語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers = Multidisciplinary Management /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers/ edited by Andrea Necchi, Philippe E. Spiess.
其他題名:
Multidisciplinary Management /
其他作者:
Spiess, Philippe E.
面頁冊數:
XVIII, 315 p. 29 illus., 26 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Internal Medicine. -
電子資源:
https://doi.org/10.1007/978-3-030-80546-3
ISBN:
9783030805463
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers = Multidisciplinary Management /
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
Multidisciplinary Management /[electronic resource] :edited by Andrea Necchi, Philippe E. Spiess. - 1st ed. 2022. - XVIII, 315 p. 29 illus., 26 illus. in color.online resource.
Introduction -- State-of-the art and ongoing developments -- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy -- Slideshow of tumor samples before and after checkpoint inhibition -- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints -- State-of-the-art and future role of molecular biomarkers for patient selection -- Background of immunotherapy trials in prostate cancer -- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer -- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy -- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC -- Benchmark of surgical safety results -- What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies -- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies. .
This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.
ISBN: 9783030805463
Standard No.: 10.1007/978-3-030-80546-3doiSubjects--Topical Terms:
668583
Internal Medicine.
LC Class. No.: RC1-1245
Dewey Class. No.: 616
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers = Multidisciplinary Management /
LDR
:03958nam a22003975i 4500
001
1092130
003
DE-He213
005
20220113181633.0
007
cr nn 008mamaa
008
221228s2022 sz | s |||| 0|eng d
020
$a
9783030805463
$9
978-3-030-80546-3
024
7
$a
10.1007/978-3-030-80546-3
$2
doi
035
$a
978-3-030-80546-3
050
4
$a
RC1-1245
072
7
$a
MJ
$2
bicssc
072
7
$a
MED045000
$2
bisacsh
072
7
$a
MJ
$2
thema
082
0 4
$a
616
$2
23
245
1 0
$a
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
$h
[electronic resource] :
$b
Multidisciplinary Management /
$c
edited by Andrea Necchi, Philippe E. Spiess.
250
$a
1st ed. 2022.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2022.
300
$a
XVIII, 315 p. 29 illus., 26 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
505
0
$a
Introduction -- State-of-the art and ongoing developments -- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy -- Slideshow of tumor samples before and after checkpoint inhibition -- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints -- State-of-the-art and future role of molecular biomarkers for patient selection -- Background of immunotherapy trials in prostate cancer -- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer -- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy -- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC -- Benchmark of surgical safety results -- What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies -- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies. .
520
$a
This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.
650
1 4
$a
Internal Medicine.
$3
668583
650
0
$a
Internal medicine.
$3
644638
700
1
$a
Spiess, Philippe E.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1075517
700
1
$a
Necchi, Andrea.
$e
editor.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1353965
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783030805456
776
0 8
$i
Printed edition:
$z
9783030805470
776
0 8
$i
Printed edition:
$z
9783030805487
856
4 0
$u
https://doi.org/10.1007/978-3-030-80546-3
912
$a
ZDB-2-SME
912
$a
ZDB-2-SXM
950
$a
Medicine (SpringerNature-11650)
950
$a
Medicine (R0) (SpringerNature-43714)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入